For perspective, keep in mind that the study was small and 13 weeks is short-term results its not clear what happened to these participants after three months
As private healthcare infrastructure grows and multinational pharmaceutical companies increase their investments, accessibility is getting better
Goldman Sachs Research estimates that GLP-1 obesity drug prescriptions could reach 30 million Americans by 2028 if coverage barriers are resolved, representing USD 150+ billion in additional annual market potential beyond current diabetes-only prescribing
The appeal should address the reasons for the denial and provide additional evidence to support the medical necessity of the GLP-1 medication
FOR INJECTION SITE REACTIONS SOURCE: DailyMed
The prevalence and incidence of IBD are rising worldwide, placing a significant burden on healthcare systems and social resources ( A promising explanation could be represented by the complex interplay between inflammation and metabolism, which is still largely unknown in the field of IBD management